Recent 8-K filings for ADCT

• July 2, 2026, 5:07 PM ET other material materiality 0.40 neutral item 5.02

  ADC Therapeutics grants $2.9M cash and 1.1M RSU retention awards to CEO, CFO, CMO

  CEO Ameet Mallik receives $1,795,500 cash and 675,000 RSUs; CFO Jose Carmona $541,842 cash and 203,700 RSUs; CMO Mohamed Zaki $568,974 cash and 213,900 RSUs.

• June 24, 2026, 9:00 AM ET other material materiality 0.65 neutral item 7.01item 8.01item 9.01

  ADC Therapeutics cuts 17% of workforce, expects $10M annual savings; pre-sBLA meeting in Aug 2026

  Workforce reduction of ~17% globally, expected to generate ~$10M annualized cost savings.

• June 3, 2026, 4:17 PM ET other material materiality 0.80 neutral item 7.01item 8.01item 9.01

  ADC Therapeutics: LOTIS-5 Phase 3 meets PFS endpoint; sBLA submission planned Q4 2026

  PFS HR=0.73 (p=0.008); median PFS 6.1 mo ZYNLONTA+ritux vs 4.7 mo R-GemOx.

• June 2, 2026, 4:01 PM ET other materiality 0.15 neutral item 5.07item 9.01 ◈ Shareholder Votes ×12

  ADC Therapeutics shareholders approve capital range increase, equity plan expansion at 2026 AGM

  Approved increase in authorized shares under 2019 Equity Incentive Plan: 46.6M for, 18.9M against.

• May 4, 2026, 7:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01 ◈ Earnings Releases

  ADC Therapeutics Q1 net product revenue $20.0M, net loss $0.21/share; cash runway into 2028

  Net product revenue $20.0M (up 15% YoY from $17.4M).

• March 10, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  ADC Therapeutics posts Q4 revenue $22.3M; net loss narrows; LOTIS-5 topline data expected Q2 2026

  Q4 net product revenue $22.3M, full year $73.6M, up from $16.4M and $69.3M respectively in 2024.

• February 23, 2026, 6:59 PM ET other material materiality 0.80 positive item 1.01item 3.02item 9.01 ◈ Material Agreements

  ADC Therapeutics cuts change-of-control payment to HCR from $750M to $150-200M; issues warrants

  Under amended HCR agreement, change-of-control payment reduced to $150M before 2028 or $200M after, from $750M previously.

• January 12, 2026, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  ADC Therapeutics posts updated corporate presentation with no material new disclosures

  ADC Therapeutics made available an updated corporate presentation dated January 2026 via 8-K filing.

• January 8, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 9.01

  ADC Therapeutics reports preliminary 2025 revenue of ~$73M; cash runway extended to 2028

  Preliminary Q4 2025 ZYNLONTA net product revenue ~$22M; full year 2025 ~$73M vs $69.3M in 2024.

• December 5, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01

  ADC Therapeutics reports 89.8% ORR and 77.6% CR in LOTIS-7 trial of ZYNLONTA + glofitamab in r/r DLBCL

  Best ORR 89.8% (44/49); CR rate 77.6% (38/49) across dose levels.

• November 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  ADC Therapeutics Q3 net product revenue $15.8M; net loss narrows to $41M; $60M PIPE strengthens cash

  Q3 net product revenue $15.8M (down 12% YoY); nine-month 2025 revenue $51.2M vs $52.9M in 2024.

• October 14, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 2.02item 3.02item 9.01 ◈ Equity Issuances ×2

  ADC Therapeutics raises $60M PIPE; prelim Q3 ZYNLONTA revenue $15.8M, cash $234.7M

  PIPE of 11.25M shares at $4.00 and 3.85M pre-funded warrants at $3.90; gross $60M, close expected Oct 27.

• September 30, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  ADC Therapeutics updates with strong LOTIS-7 combo data; ZYNLONTA expansion plans detailed

  LOTIS-7 (ZYNLONTA+glofitamab) achieved 86.7% CR rate in r/r LBCL; 93.3% ORR in evaluable patients (N=30).

• August 12, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  ADC Therapeutics Q2 net loss widens to $56.6M; completes $100M PIPE, cuts workforce 30%

  Q2 product revenue $18.1M (+6% YoY); net loss $56.6M ($0.50/share) vs $36.5M loss ($0.38) in Q2 2024.

• June 12, 2025, 7:59 PM ET other material materiality 0.85 neutral item 1.01item 2.05item 3.02item 9.01 ◈ Restructurings & Charges

  ADC Therapeutics announces $100M private placement and restructuring with 30% workforce cut

  $100M private placement: 13.03M shares at $3.53 & 15.73M pre-funded warrants at $3.432; close June 16, 2025.

• June 5, 2025, 7:59 PM ET leadership materiality 0.35 neutral item 5.07item 9.01

  ADC Therapeutics elects Timothy Coughlin to board at 2025 AGM; all proposals pass

  Timothy Coughlin elected to board; CPA, former Neurocrine CFO, appointed audit committee chair.

• May 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  ADC Therapeutics Q1 net loss narrows to $38.6M; ZYNLONTA revenue $17.4M, LOTIS-7 shows 95.5% ORR

  Q1 product revenue $17.4M vs $17.8M YoY; license revenue $5.6M including $5M Canadian milestone.

• March 27, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  ADC Therapeutics reports Q4/FY2024 results: net loss narrows; ZYNLONTA revenue flat; cash runway to H2 2026

  Net loss Q4 2024 was $30.7M ($0.29/share) vs $85.0M ($1.03) in Q4 2023; full year net loss $157.8M ($1.62) vs $240.1M ($2.94).

• January 13, 2025, 6:59 PM ET earnings materiality 0.50 neutral item 2.02item 7.01item 9.01

  ADC Therapeutics releases preliminary 2024 ZYNLONTA sales and expense data at JPM conference

  Preliminary ZYNLONTA net sales and FY2024 expenses disclosed at JPMorgan Healthcare Conference; no specific figures in filing.

• November 13, 2024, 6:59 PM ET other materiality 0.15 neutral item 5.07item 9.01

  ADC Therapeutics shareholders approve capital range increase and conditional share capital amendments

  Shareholders approved amendment to Article 4a to increase capital range (52.4M for, 9.0M against).

• November 7, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  ADC Therapeutics reports Q3 2024 revenue $18.0M; net loss narrows; discontinues ADCT-601

  ZYNLONTA net product revenue $18.0M in Q3 2024 vs $14.3M in Q3 2023; year-to-date $52.9M.

• August 6, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  ADC Therapeutics Q2 2024: ZYNLONTA $17M (−5% QoQ), net loss $36.5M, cash extended to mid-2026

  ZYNLONTA net sales $17.0M in Q2 2024 (−5% QoQ, −11% YoY); commercial profitability achieved.

• June 14, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07item 9.01

  ADC Therapeutics shareholders approve all 12 proposals at 2024 AGM, including director re-elections and compensation

  Shareholders approved management report, annual financial statements, and discharge of directors/executive committee for FY2023.

• May 14, 2024, 7:59 PM ET other materiality 0.15 neutral item 7.01item 9.01

  ADC Therapeutics posts corporate presentation; no material new disclosures identified

  Presentation dated May 14, 2024 made available for industry conferences and investor meetings.

• May 8, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  ADC Therapeutics raises ~$105M in public offering of common shares and pre-funded warrants

  Offered 13.4M common shares at $4.90/share and pre-funded warrants for 8.2M shares at $4.812/warrant.

• May 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  ADC Therapeutics Q1 net loss narrows to $46.6M; ZYNLONTA sales $17.8M; initial MZL data shows 13/15 CR

  ZYNLONTA net sales $17.8M in Q1 2024, up 7% QoQ, down 6% YoY; total operating expenses down 25%.

• April 9, 2024, 7:59 PM ET other material materiality 0.25 neutral item 7.01item 9.01

  ADC Therapeutics presents exatecan-based ADC platform at virtual investor event

  CEO Ameet Mallik and CSO Patrick van Berkel to present updates on novel exatecan-based ADC platform.

• March 13, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  ADC Therapeutics reports Q4'23 ZYNLONTA sales $16.6M, net loss $85M; cash runway into Q4'25

  ZYNLONTA net sales $16.6M in Q4'23 (+17% QoQ, -16% YoY); FY'23 $69.1M (-8% YoY).

• March 5, 2024, 6:59 PM ET other materiality 0.05 neutral item 7.01item 9.01

  ADC Therapeutics presents at Cowen conference; no material updates disclosed

  Filed Form 8-K on March 5, 2024, to disseminate a corporate presentation.

• February 29, 2024, 6:59 PM ET other material materiality 0.35 neutral item 5.02item 9.01

  ADC Therapeutics SA Board approves Annual Bonus Plan for 2024

  Plan effective retroactively from Jan 1, 2024; bonuses based on corporate objectives approved by Board or Compensation Committee.

• January 24, 2024, 6:59 PM ET other material materiality 0.40 neutral item 1.01item 9.01 ◈ Material Agreements

  ADC Therapeutics grants Redmile preemptive rights up to 20% ownership threshold

  Agreement preserves Redmile's preemptive and advance subscription rights if group holds ≤20% of share capital.

• January 19, 2024, 6:59 PM ET debt materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  ADC Therapeutics amends loan; adds ZYNLONTA sales covenant, eases out-license repay

  New revenue covenant requires ZYNLONTA net sales from $45.5M (trailing 3Q Jun'24) to $94.2M (4Q Jun'29).

• January 4, 2024, 6:59 PM ET other material materiality 0.65 neutral item 2.02item 7.01item 9.01

  ADC Therapeutics reports preliminary ZYNLONTA Q4 net sales ~$16.5M; cash ~$278.5M

  Preliminary ZYNLONTA Q4 2023 net sales ~$16.5M, double-digit percentage increase from Q3 2023.

• January 4, 2024, 6:59 PM ET other materiality 0.40 positive item 8.01

  ADC Therapeutics regains NYSE minimum bid price compliance; removed from noncompliant list

  Received NYSE notice on Jan 2, 2024 confirming compliance with Section 802.01C.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.62 · Most common event other_material

6 positive 3 negative 25 neutral

source · ADCT on sec.gov